Finance

Lists
GIFLF:OTCMKTS
Grifols SA Class A
USD 11,13
0,00%
(0,00) 1D
15 Sep., 15:11:14 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GIFLF...
Mkt. cap
6,64 mjd
Avg. vol.
543,00
Volume
0,00
52-wk high
USD 12,90
52-wk low
USD 10,13
Beta
0,86
Shares outstanding
426,13 m
No. of employees
25 k
Mkt. cap
6,64 mjd
Avg. vol.
543,00
Volume
0,00
52-wk high
USD 12,90
52-wk low
USD 10,13
Beta
0,86
Shares outstanding
426,13 m
No. of employees
25 k
News stories
From web sources and news partners
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A
CEONacho Abia
Employees25 k
Founded18 Nov. 1940
Headquarters-
Sector-
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,87 mjd
1,98 mjd
1,70 mjd
1,87 mjd
Cost of goods sold
1,11 mjd
1,28 mjd
1,06 mjd
1,19 mjd
Cost of revenue
1,11 mjd
1,28 mjd
1,06 mjd
1,19 mjd
Research and development expenses
97,01 m
90,82 m
90,00 m
86,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
273,76 m
262,86 m
269,00 m
301,00 m
Operating expense
370,34 m
353,11 m
359,00 m
387,00 m
Total operating expenses
1,48 mjd
1,63 mjd
1,42 mjd
1,58 mjd
Operating income
381,18 m
347,38 m
280,00 m
298,00 m
Other non operating income
-
-33,00 m
-
-13,00 m
EBT including unusual items
198,13 m
111,10 m
112,00 m
247,00 m
EBT excluding unusual items
227,20 m
183,10 m
143,00 m
216,00 m
Income tax expense
54,71 m
-14,68 m
24,00 m
64,00 m
Effective tax rate
27,61%
-13,21%
21,43%
25,91%
Other operating expenses
-430,00 k
-570,00 k
-
-
Net income
126,96 m
98,25 m
73,00 m
154,00 m
Net profit margin
6,81%
4,96%
4,29%
8,22%
Earnings per share
-
-
-
-
Interest and investment income
-
36,00 m
-
120,00 m
Interest expense
-156,07 m
-107,99 m
-139,00 m
-179,00 m
Net interest expenses
-156,07 m
-71,99 m
-139,00 m
-59,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
484,03 m
422,88 m
384,00 m
364,00 m
Gain or loss from assets sale
-
2,00 m
-
-6,00 m
AI content may include mistakes. Learn more
Google-programme